BofA analyst Greg Harrison downgraded Sangamo to Neutral from Buy with a price target of $5, down from $8. Given the "challenging macro environment," the analyst favors SMid biotech companies with "derisked late-stage assets, low financing risk, and truly differentiated platforms." Harrison cites limited near-term clinical catalysts in the next 12 months for the downgrade of Sangamo.
Published first on TheFly
